[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"dry-eye-syndromes\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:dry-eye-syndromes":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,18,0,[8,44,72,95,119,149,174,198,220,246,269,294,314,341,366,384,412,433],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":4},"100585534","phase-3-phase-iii-study-of-topical-fibrinogen-depleted-human-platelet-lysate-compared-to-placebo-for-moderate-to-severe-dry-eye-100585534",false,"NCT06903611","Phase III Study of Topical Fibrinogen-Depleted Human Platelet Lysate Compared to Placebo for Moderate to Severe Dry Eye","CAMOMILE-2: Phase III Randomized, Double-Masked, Safety and Efficacy Study of Topical Fibrinogen-Depleted Human Platelet Lysate Compared to Vehicle Control for the Treatment of Moderate to Severe Dry Eye","CAMOMILE-2","Inclusion Criteria:\n\n1. Male or female subjects who at the time of consent are 18 years of age or older, if participating at a study site located in the U.S.\n2. Having a self-reported history of dry eye disease within the past 6 months.\n3. NEI Corneal Fluorescein Staining Score in at least one eye at screening and at Day 0 (pre-randomization) that is ≥ 6 (total score)as determined by the investigator.\n4. Visual Analog Scale (VAS) Symptom Index-Eye Dryness\u002FEye Discomfort total score (pre-dose) that is ≥ 40 points at screening and at Day 0 (pre-randomization).\n5. Willingness to have both the right and left eyes treated in the study.\n6. Willingness to discontinue contact lenses and all current DED treatments except artificial tears.\n7. Be able to demonstrate ability to use study medication bottle; this can be documented on study bottle used during washout period.\n8. Female subjects must be either: (1) of non-childbearing potential; or, (2) of childbearing potential and using an acceptable method of birth control with a negative pregnancy test :\n\n   1. Females of Non-childbearing Potential: Surgically sterilized (e.g., hysterectomy or bilateral oophorectomy) prior to screening; or, post-menopausal (i.e., no menstrual bleeding for at least 1 year prior to screening; or with a negative pregnancy test if less than 1 year post-menopausal).\n   2. Females of Childbearing Potential: Must agree to use a highly effective acceptable form of birth control (e.g., established hormonal birth control, or double barrier method: intrauterine device plus condom or spermicidal gel plus condom) from 21 days prior to dosing until 7 days after dosing.\n9. Providing written Informed Consent consistent with privacy language as per national regulations (e.g., HIPAA authorization) with signature obtained from the subject or legally authorized representative prior to the performance of any study related procedures (including withdrawal of prohibited medication.\n10. Willingness and ability to comply with schedule for follow-up visits and postoperative evaluations.\n\n    \\-\n\nExclusion Criteria:\n\n* Subjects who meet any of the following exclusion criteria for one or both eyes at screening will not be enrolled in the study. Subjects who meet any of the following exclusion criteria for one or both eyes on Day 0 will not be randomized and will be withdrawn from the study as screen failures:\n\n  1. Any abnormal lid anatomy or blinking function in either eye.\n  2. Using any topical ocular treatment other than the following medications:\n\n     a. Artificial Tears: Preservative-free artificial tears may be used as needed before and\u002For during the study. Whenever practicable, the same brand of artificial tears should be used throughout the study and its use documented in the patient diary throughout study participation.\n  3. Previous ocular surgery of any type (including lacrimal, corneal and trauma), except:\n\n     1. Non-refractive laser eye surgery of any type in either eye performed more than 3 months before screening is permitted.\n     2. Refractive surgery in either eye performed more than 6 months before screening is permitted.\n     3. Cataract surgery in either eye performed more than 3 months before screening is permitted\n  4. Any ocular anomaly that, in the investigator's opinion, interferes with the ocular surface, including:\n\n     1. Active ocular herpes simplex virus infection\n     2. Recurrent corneal erosion\n     3. Symptomatic epithelial basement membrane dystrophy\n     4. Mucus fishing syndrome\n     5. Giant papillary conjunctivitis\n     6. Post-radiation keratitis\n     7. Stevens-Johnson syndrome\n     8. Corneal ulcer\n     9. Abnormalities of the nasolacrimal drainage system\n     10. Chemical injury\n     11. Diagnosed significant anterior blepharitis and\u002For progressive pterygium\n  5. Current history of ocular infection (viral, bacterial, fungal), disease or inflammation (e.g., uveitis) not associated with dry eye, unless the disorder or disease is, in the investigator's opinion:\n\n     1. Stable for at least 3 months before the Screening Visit; and,\n     2. Not likely to impact or possibly interfere with the interpretation of study results.\n  6. Subjects with a current intraocular infection or with any other current eye or systemic condition (e.g., severe endothelial corneal dystrophy) that, in the investigator's opinion, would interfere with the dry eye evaluation or treatment, or for which the potential benefits of CAM-101 do not outweigh the risks.\n  7. History of ocular allergy (including seasonal conjunctivitis) or chronic conjunctivitis other than that secondary to dry eye.\n  8. Known hypersensitivity to the components of CAM-101 or the vehicle control (fibrinogen-depleted human platelet lysate; Plasma-Lyte A).\n  9. Known hypersensitivity to one of the procedural medications (e.g., proparacaine, fluorescein) unless a suitable alternative medication is available.\n  10. Inability to refrain from contact lens wear during the study, including the vehicle control run-in period.\n  11. Anticipated need for temporary or permanent punctum plugs during the study. (If punctum plugs have been in place for at least 4 weeks prior to the screening visit, the plugs are allowed to remain in place during the study. ) Patients must remain symptomatic for DED post punctal plug insertion.\n  12. Any ocular disease or ocular condition not stabilized within 1 month (30 days) before the screening visit.\n  13. Any clinically significant systemic disease or condition that is inadequately controlled (e.g., diabetes, thyroid disease, autoimmune disease) or not stabilized within 4 weeks before the screening visit.\n  14. Inability or unwillingness to discontinue use of autologous serum eye drops or platelet rich plasma eye drops during the 2-week run-in period and throughout the remainder of the study.\n  15. Female subjects who are pregnant or lactating or plan to become pregnant during the course of the study.\n  16. Subjects not under legal guardianship who, in the investigator's opinion, lack the mental capacity to provide written informed consent for study participation.",true,"ALL","18 Years",{"count":21,"type":22},475,"ESTIMATED","INTERVENTIONAL",[25],"PHASE3","Prospective, multicenter, randomized, vehicle-controlled, double-masked, study of CAM-101 topical ophthalmic solution compared to vehicle control followed by crossover to long-term follow-up open-label treatment with CAM-101 for one year.",[28,29,30,31],"Dry Eye Disease","Dry Eye","Dry Eyes Chronic","Dry Eye Syndromes","NOT_YET_RECRUITING","2026-06-11",{"date":35,"type":36},"2026-06-12","ACTUAL",{"date":38,"type":22},"2026-10-01",{"date":40,"type":22},"2028-12",{"name":42,"class":43},"Cambium Bio Limited","INDUSTRY",{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":23,"phases":53,"briefSummary":55,"conditions":56,"keywords":58,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":71},"100639590","the-effect-of-rinsing-on-ocular-inflammation-and-symptoms-in-patients-with-dry-eye-disease-100639590","NCT07618364","The Effect of Rinsing on Ocular Inflammation and Symptoms in Patients With Dry Eye Disease","RINSE-A","Inclusion Criteria:\n\n* MMP-9 Positivity in both eyes\n\nExclusion Criteria:\n\n* Active ocular infection, including bacterial, viral, or fungal conjunctivitis Acute allergic conjunctivitis or severe seasonal ocular allergy flare History of autoimmune ocular surface disease (e.g., Sjögren syndrome, ocular cicatricial pemphigoid, Stevens-Johnson syndrome) Current use of topical anti-inflammatory medications, including corticosteroids, cyclosporine, lifitegrast, or topical NSAIDs within 14-30 days prior to enrollment Initiation of new ocular or systemic anti-inflammatory therapy during the study period Contact lens wear within 12-24 hours prior to testing Ocular surgery or laser procedures within the previous 3-6 months Current punctal plug use or punctal occlusion procedures within the prior 3 months Severe aqueous-deficient dry eye preventing adequate tear sample acquisition or reliable InflammaDry testing Use of preserved artificial tears within a specified washout period Eyelid abnormalities or active blepharitis requiring treatment Pregnancy or breastfeeding (optional depending on IRB requirements) History of hypersensitivity to saline irrigation or study materials Any systemic inflammatory disease judged by investigators to confound tear film MMP-9 level",{"count":52,"type":22},33,[54],"NA","The central hypothesis is that inflammation contributes to dry eye and that rinsing the palpebral conjunctiva, bulbar conjunctiva, and fornices will reduce the inflammatory burden on the ocular surface.",[31,29,57],"Ocular Surface Disease",[59,60],"ophthalmology","optometry","RECRUITING","2026-05-26",{"date":64,"type":36},"2026-06-01",{"date":66,"type":36},"2022-01-01",{"date":68,"type":22},"2027-12-01",{"name":70,"class":43},"Rinsada",1,{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":80,"enrollmentInfo":81,"targetDuration":4,"studyType":23,"phases":83,"briefSummary":84,"conditions":85,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":4},"100624876","lacrima-vr-for-dry-eye-disease-and-meibomian-gland-dysfunction-100624876","NCT07415330","Lacrima VR for Dry Eye Disease and Meibomian Gland Dysfunction","A Randomized, Masked (Evaluator), Sham-Controlled, Prospective Study to Evaluate the Safety and Effectiveness of the Lacrima VR System in Subjects With Dry Eye Disease and Meibomian Gland Dysfunction","CLN-0154","Inclusion Criteria:\n\n* Adults aged 18 years and older\n* Ability to provide written informed consent\n* Willingness and ability to comply with study procedures and visits\n* Self-reported dry eye symptoms for at least 3 months\n* OSDI score ≥ 23 at baseline\n* Tear Break-Up Time (TBUT) \\\u003C 10 seconds in both eyes\n\nExclusion Criteria:\n\n* Ocular surgery within 1 year prior to screening\n* Active ocular infection or inflammation\n* History of ocular herpes infection within the past 3 months\n* Use of contact lenses within 3 months prior to screening or during the study\n* Use of prohibited dry eye or MGD treatments within protocol-defined washout periods\n* Diagnosis of epilepsy\n* Intraocular pressure \\> 20 mmHg\n* Pregnancy or breastfeeding","120 Years",{"count":82,"type":22},20,[54],"This is a prospective, multi-center, randomized, sham-controlled clinical investigation designed to evaluate the safety and effectiveness of the Lacrima VR system in adult subjects with Dry Eye Disease (DED) and Meibomian Gland Dysfunction (MGD). Subjects will be randomized in a 1:1 ratio to receive either active Lacrima VR treatment or a sham device with reduced luminance. Effectiveness will be assessed primarily by change in Tear Break-Up Time (TBUT), and safety will be evaluated by the incidence of device-related adverse events.",[29,31],"2026-05-11",{"date":88,"type":36},"2026-05-12",{"date":90,"type":22},"2026-07-20",{"date":92,"type":22},"2026-09-01",{"name":94,"class":43},"Demaod Ltd",{"id":96,"slug":97,"hasResults":11,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":4,"eligibilityCriteria":101,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":102,"targetDuration":4,"studyType":23,"phases":104,"briefSummary":105,"conditions":106,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":118},"100533027","therapeutic-efficacy-and-safety-of-non-invasive-rf-treatment-in-refractory-mgd-100533027","NCT06220474","Therapeutic Efficacy and Safety of Non-Invasive RF Treatment in Refractory MGD","Therapeutic Efficacy and Safety of Non-Invasive Radiofrequency Treatment in Patients With Refractory Meibomian Gland Dysfunction: A Randomized Controlled Trial","Inclusion Criteria:\n\n1. Age 18 or more\n2. Bilateral dry eye disease as confirmed by presence of both symptoms and signs 2.1 Symptoms: Abnormal result on the Standard Patient Evaluation of Eye Dryness Questionnaire (SPEED) dry eye symptom questionnaire (≥5) 2.2 Signs: Abnormal result in at least one of the following three clinical tests - tear osmolarity, NIKBUT and corneal staining for punctate epithelial erosions and,\n3. Bilateral moderate to severe meibomian gland dysfunction - at least Grade 1 meibum quality (cloudy appearance) and Grade 2 meibum expressibility (moderate pressure required). And,\n4. Refractory MGD - The failure to respond to at least three types of conventional therapy, including artificial tears, topical or systemic antibiotics and anti-inflammatory treatments and the aforementioned heat-based therapies, over a period of at least 2 years\n5. Fitzpatrick skin type I-IV - Type V and VI skinned subjects are excluded from the study due to the high risk of pain and focal hypopigmentation\n6. Mentally fit to give informed consent\n\nExclusion Criteria:\n\n1. Fitzpatrick skin type V-VI\n2. History of eyelid scarring\n3. Infrared meibography evidence of significant acinar gland atrophy (dropout of \\>30%) - these patients have been shown not to benefit from heat-based therapies due to end-stage disease\n4. Pregnancy or lactation\n5. Active corneal disease such as infectious keratitis, allergic keratoconjunctivitis, pterygium, exposure keratopathy, lagophthalmos, trichiasis or dellen\n6. Current systemic intake of photosensitive medications, including tetracycline group of drugs.\n7. History of corneal abnormality or surgery within 3 months",{"count":103,"type":22},112,[54],"The goal of this prospective, 24-week, double-masked, randomized, sham-controlled clinical trials to compare clinical efficacy and safety of RF and MGX with MGX alone in patients with meibomian gland dysfunction-related dry eye disease. The main question it aims to answer is whether radiofrequency treatment and meibomian gland expression is more effective in improving tear breakup time, as measured using non-invasive video keratography, compared with meibomian gland expression alone, in patients with refractory meibomian gland dysfunction-related dry eye disease.\n\nParticipants will be divided into two groups, one group will receive RF treatment followed with MGX and another will receive sham treatment with MGX.",[31,107],"Meibomian Gland Dysfunction","2026-04-24",{"date":110,"type":36},"2026-04-27",{"date":112,"type":36},"2024-10-22",{"date":114,"type":22},"2027-12-31",{"name":116,"class":117},"The University of Hong Kong","OTHER",2,{"id":120,"slug":121,"hasResults":11,"nctId":122,"briefTitle":123,"officialTitle":124,"acronym":4,"eligibilityCriteria":125,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":126,"enrollmentInfo":127,"targetDuration":4,"studyType":23,"phases":129,"briefSummary":130,"conditions":131,"keywords":133,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":4},"100626015","blink-reminders-and-meibomian-gland-loss-in-digital-screen-users-100626015","NCT07430137","Blink Reminders and Meibomian Gland Loss in Digital Screen Users","Effect of a Blink Reminder Program on the Progression of Meibomian Gland Loss in Intensive Digital Screen Users: a Randomized Controlled Trial With Infrared Meibography","Inclusion Criteria:\n\n* Participants aged 18 to 40 years.\n* Intensive digital screen users, defined as an average screen time of ≥4 hours per day for at least 3 days per week.\n* Ocular Surface Disease Index (OSDI) score ≥13 (indicating mild to severe symptoms).\n* Non-invasive tear break-up time (NIBUT) ≤10 seconds measured by infrared meibography.\n* Presence of visible Meibomian glands on baseline meibography, allowing for quantitative analysis.\n* Technical ability to install and operate the BlinkEasy software on their primary digital device.\n\nExclusion Criteria:\n\n* Active ocular disease, including infections, corneal ulcers, or acute conjunctivitis.\n* History of ocular surgery (e.g., refractive surgery, cataract extraction) or significant ocular injury.\n* Use of topical ophthalmic medications affecting the ocular surface (e.g., steroids, glaucoma medications, or cyclosporine) within the last 3 months.\n* Active use of contact lenses that cannot be suspended for the duration of the 12-week study period.\n* Systemic conditions known to affect the ocular surface (e.g., Sjögren's syndrome, Rheumatoid Arthritis).\n* Diagnosis of Diabetes Mellitus (Type 1 or Type 2).","40 Years",{"count":128,"type":22},28,[54],"This randomized clinical trial aims to evaluate if a blink reminder program ('BlinkEasy') reduces the progression of Meibomian gland loss in intensive digital screen users over three months , using infrared meibography as the primary structural measure. Additionally, the study will analyze changes in dry eye symptoms using the 12-item Ocular Surface Disease Index (OSDI) questionnaire and non-invasive tear break-up time (NIBUT).",[31,132],"Meibomian Gland Dysfunction (Disorder)",[134,135,136,137,138,139],"Dry eye","Blinking","Meibography","Digital Displays","Meibomian Gland Atrophy","BlinkEasy","2026-02-25",{"date":142,"type":36},"2026-02-27",{"date":144,"type":22},"2026-02-19",{"date":146,"type":22},"2026-08",{"name":148,"class":117},"Asociación para Evitar la Ceguera en México",{"id":150,"slug":151,"hasResults":11,"nctId":152,"briefTitle":153,"officialTitle":154,"acronym":4,"eligibilityCriteria":155,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":156,"targetDuration":4,"studyType":23,"phases":158,"briefSummary":159,"conditions":160,"keywords":162,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":118},"100624686","clinical-investigation-between-the-topical-administration-of-a-tear-substitute-with-ancillary-medicinal-substance-and-hyaluronic-acid-03-fbv01-vs-hyaluronic-acid-03-in-subjects-in-the-treatment-from-moderate-to-severe-ded-100624686","NCT07412860","Clinical Investigation Between the Topical Administration of a Tear Substitute With Ancillary Medicinal Substance and Hyaluronic Acid 0.3% (FBV_01) vs Hyaluronic Acid 0.3% in Subjects in the Treatment From Moderate to Severe DED","Interventional, Multi-center, Randomized, Controlled, Open Label Clinical Investigation Between the Topical Administration of a Tear Substitute Containing Ancillary Medicinal Substance and Hyaluronic Acid 0.3% (FBV_01) Versus Hyaluronic Acid 0.3% in Subjects in the Treatment From Moderate to Severe Dry Eye Syndrome","Inclusion Criteria:\n\n* Patients able to provide written Informed Consent, in accordance with good clinical practice and current legislation;\n* Patients (male and female) 18 years of age or older with moderate to severe dry eye syndrome or with dry eye syndrome, even after eye surgery (e.g. refractive surgery or cataract);\n* Moderate to severe dry eye syndrome in one or both eyes in the presence of:\n\n  1. Dry Eye Symptom Assessment Questionnaire (SANDE) \\> 60;\n  2. Tear Film Break-Up Time (TFBUT) \\\u003C 7 seconds. TFBUT value will be recorded as an average of 3 measurements;\n  3. Test di Schirmer \\\u003C 10 mm;\n* Diagnosis of dry eye syndrome for at least 6 months (use or recommendation of use of artificial tears\u002Flubricants for the treatment of dry eye);\n* Patients able to understand the nature and purpose of the study, including possible risks;\n* Patient able to cooperate with the Investigator and meet the requirements of the clinical investigation plan;\n* Patient who, in the opinion of the Investigator, will benefit from this treatment;\n* Patient available for the entire study period.\n\nExclusion Criteria:\n\n* Eye infection or clinically significant inflammation in both eyes (for example: Herpes simplex infections, corneal virus infections, bacterial, viral or fungal conjunctivitis, tuberculosis and mycosis of the eye, purulent and herpetic blepharitis, stye);\n* History or evidence of eyelid abnormalities in either eye;\n* Use of topical cyclosporine, topical corticosteroids, or any other topical medication for the treatment of ocular pathologies in either eye within 7 days of study enrollment;\n* Patients being treated with chronic systemic therapies with analgesic, anti-inflammatory, corticosteroids, or opioids;\n* History of ocular surgery (including laser procedures or refractive surgery) in either eye 7 days prior to enrollment;\n* History or evidence of severe or uncontrolled systemic or autoimmune disease does not allow participation in the study or could impair the results;\n* Patients being treated with drugs and\u002For medical devices and\u002For supplements for neuropathic pain (e.g., SNRIs (duloxetine, venlafaxine), pregabalin, gabapentin, TCAs (nortriptyline, amitriptyline));\n* Patient with known or potential allergy or hypersensitivity and\u002For history of allergic reactions to one of the components of the medical device;\n* Participation in another clinical trial within 30 days prior to the screening visit;\n* History of administration or abuse of drugs, medications, or alcohol;\n* Women of childbearing potential (those who are not surgically sterilized or post-menopausal for at least 1 year) will be excluded from participation in the study if they meet any of the following conditions:\n\n  1. are currently pregnant or,\n  2. have a positive urine pregnancy test result at visit 1,\n  3. intend to become pregnant during the study treatment period or,\n  4. are breastfeeding or, unwilling to resort to highly effective birth control measures, such as: hormonal contraceptives oral, implanted, transdermal or injected and\u002For mechanical barrier methods spermicidal concurrently with a barrier such as a condom or diaphragm or IUD during the entire course of the study and 30 days after the end of the treatment period;\n* Subject unable to follow clinical investigation procedures and follow-up visits;\n* Any other medical condition which, in the opinion of the Investigator, could influence participation in the clinical investigation or compromise its results.",{"count":157,"type":22},74,[54],"The goal of this clinical investigation plan is to evaluate the performance, tolerability, safety, and compliance of an ophthalmic solution containing an ancillary medicinal substance and hyaluronic acid 0.3% (FBV\\_01) compared with hyaluronic acid 0.3% alone in adult men and women (≥18 years) with moderate-to-severe dry eye syndrome.\n\nThe main questions it aims to answer are:\n\n* Is the ophthalmic solution containing an ancillary medicinal substance and hyaluronic acid non-inferior in improving the clinical performance outcomes of dry eye compared with hyaluronic acid alone?\n* Is the investigational device safe and well tolerated, with acceptable partecipant compliance over the treatment period?\n\nResearchers will compare the medical device containing an ancillary medicinal substance and hyaluronic acid 0.3% (FBV\\_01) to hyaluronic acid 0.3% alone to see if the combination provides at least equivalent clinical benefit without increased safety issues.\n\nParticipants will be randomly assigned (1:1) to one of two treatment groups in a multicenter, prospective, randomized, open-label, controlled study. Participants will instill 1 drop in both eyes 4 times daily (every 4 ± 1 hours) for 30 ± 4 days and attend study visits for assessments of dry eye signs and symptoms, safety, tolerability, and treatment compliance. The study plans to enroll 74 partecipants, with an enrollment period of about 11 months and a total study duration of approximately 12 months (from first partecipant first visit to last partecipant last visit).",[31,161],"Dry Eye Disease (DED)",[163,164],"moderate to severe dry eye syndrome","dry eye disease","2026-02-09",{"date":167,"type":36},"2026-02-17",{"date":169,"type":36},"2025-03-26",{"date":171,"type":22},"2026-03-31",{"name":173,"class":43},"FB Vision S.p.A",{"id":175,"slug":176,"hasResults":11,"nctId":177,"briefTitle":178,"officialTitle":179,"acronym":4,"eligibilityCriteria":180,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":181,"targetDuration":4,"studyType":23,"phases":183,"briefSummary":184,"conditions":185,"keywords":187,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":189,"lastUpdatePostDateStruct":190,"startDateStruct":192,"completionDateStruct":194,"leadSponsor":196,"locationsCount":118},"100544623","photobiomodulation-with-red-vs-blue-light-rebel-100544623","NCT06371300","Photobiomodulation With REd vs BluE Light (REBEL)","Photobiomodulation of the Ocular Surface and Eyelids With Different Wavelengths: REd vs BluE Light (REBEL)","Inclusion Criteria:\n\n* Individuals with dry eye disease symptoms (Ocular Surface Disease Index questionnaire (OSDI) score ≥ 13 or Dry Eye Questionnaire (DEQ5) score \\> 6) and signs (tear film instability measured with non-invasive tear break-up time \\\u003C 10 s or ocular surface damage measured using special dyes placed on the front surface of the eyes that temporarily stains any aggravated or damaged cells: \\> 5 corneal spots, \\> 9 conjunctival spots or lid margin staining ≥ 2mm in length and ≥ 25% in width)\n* Individuals need to also have Meibomian gland dysfunction. The diagnosis of Meibomian gland dysfunction depends on how many of 5 glands in the central lower eyelid can express oil, and the quality of the oil. A diagnosis is made if there is decreased expressibility (grade 1-3 on the Pflugfelder scale) and reduced quality of oil (grade 1-3 on Bron scale). Any presence of gland blockage and\u002For loss of oil glands grade 1 to grade 4 of either eyelid \\[Pult and Reide-Pult, 2013\\]) will also justify a diagnosis of Meibomian gland dysfunction.\n* Individuals will also need to have ocular demodicosis, diagnosed by clinical observation on slit lamp biomicroscope based on signs including collarettes around the base of lashes, visible Demodex tails, or excessive pouting of lash follicles in those with good lid hygiene where Demodex was confirmed by secondary means such as visible Demodex tails.\n* Age ≥ 18 years, male or female\n* Able to provide written consent in English\n* Able to attend a total of 4 visits: 3 treatment visits and followed up for 1 month after final treatment\n\nExclusion Criteria:\n\n* Pregnancy\n* Ocular light-based therapies including intense pulsed light (IPL) or LLLT treatment within the past 1 month or during study period in addition to those provided in the study\n* Contact lens wear in the past 2 weeks or during study period\n* Other active ocular surface diseases or history of ocular surgery or corneal infections the past 6 months",{"count":182,"type":22},36,[54],"The use of photobiomodulation or low-level light therapy (LLLT) in the ophthalmic field stemmed from dermatology which has shown impact on skin blood flow and regeneration. There has been a rise in clinical interest with emerging evidence in the benefits of photobiomodulation in managing chronic inflammatory conditions such as dry eye disease including improvements in ocular discomfort symptoms, tear film stability and tear volume. Despite the observed clinical benefits, limited research has been done to compare photobiomodulation utilising different wavelengths, as most research on dry eye disease has focused on red wavelengths. It has been purported that blue wavelengths may disrupt microbial growth while red wavelengths stimulate energy production and hence increase heat in the affected tissues, although research into these differential impacts at the ocular surface and external eye has been limited. Hence, the aim of this exploratory clinical trial is to compare the impact of using LLLT incorporating red versus blue wavelengths on eyelid haemodynamics and microbiome, as well as conventional ocular surface measures of patients with dry eye disease and blepharitis (inflammation of the eyelids).\n\nParticipants with dry eye disease, oil gland disruption and blepharitis will receive 3 treatments with these LLLT, each separted by 1 week apart, and followed up to 1 month after the final treatment session. Participants will be randomised to either of 3 groups: Red light only group, Red + Blue light group, or a sham treatment group.",[31,107,186],"Blepharitis",[188],"Low-level light therapy","2026-01-19",{"date":191,"type":36},"2026-01-21",{"date":193,"type":36},"2024-05-01",{"date":195,"type":22},"2026-12-30",{"name":197,"class":117},"Aston University",{"id":199,"slug":200,"hasResults":11,"nctId":201,"briefTitle":202,"officialTitle":203,"acronym":204,"eligibilityCriteria":205,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":206,"targetDuration":4,"studyType":23,"phases":207,"briefSummary":208,"conditions":209,"keywords":211,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":189,"lastUpdatePostDateStruct":215,"startDateStruct":216,"completionDateStruct":218,"leadSponsor":219,"locationsCount":71},"100528685","protecting-the-eyes-of-gamers-with-lubricating-eyedrops-100528685","NCT06163989","Protecting the Eyes of Gamers With Lubricating Eyedrops","The Protective Impact of TheaLoz Duo Eyedrop on the Ocular Surface in Hand-Held Console and Computer Game Users","PROTEGE","Inclusion criteria:\n\n* Individuals with dryness symptoms as assessed with the Ocular Surface Disease Index (OSDI score ≥ 13).\n* Individuals who play handheld console and computer-based games ≥ 2 hours everyday on average\n* Individuals who are comfortable and competent at using smartphone applications\n* Age ≥ 18 years, male or female\n* Able to provide written consent in English\n* Able to instil the treatment lubricating eyedrop on their own, and return any provided eyedrop bottle to the researcher used at the end of the treatment\n* Able to attend multiple visits (3 visits over 2 months)\n\nExclusion criteria:\n\n* Pregnancy\n* Use of any topical ocular medical eyedrops or lubricants in the 1 week prior to starting the study or during the study period. Those who are using existing lubricating eyedrops and are interested in participating will be required to stop their lubricating eyedrops for 1 week prior to commencing the study\n* History of ocular surgery, trauma or infections in the past 6 months",{"count":128,"type":22},[54],"The excessive use of screens particularly amongst digital gamers can adversely impact the health of the surface of the eyes with symptoms and signs of surface damage. While strategies including limiting screen time exist, these may be ineffective given the widespread rise of digital device use and gaming culture in the modern era. There is limited evidence for the protective effect of lubricating eyedrops on the ocular surface for handheld console and computer gamers.\n\nThe aim of this study is to investigate the protective effect of a lubricating eyedrop (TheaLoz Duo) on the surface of the eyes in handheld console and computer gamers. The main question it aims to answer is whether TheaLoz Duo could protect the surface of the eyes from dessication and alleviate symptoms of dry eye disease in handheld console and computer gamers.\n\nParticipants will receive either the lubricating eyedrop first for 1 month, followed by a control condition (no eyedrops) for another month, or the other way round. Participants will attend 3 visits in total, each separated by 1 month apart. During each visit, routine clinical assessments of the front of the eye will be conducted. Subsequent findings from this timely study will help improve care of the surface of the eyes for a growing population of gamers worldwide.",[31,210],"Computer Vision Syndrome",[212,213,214],"Lubricating eyedrop","Artificial tears","Ocular surface",{"date":191,"type":36},{"date":217,"type":36},"2024-09-01",{"date":195,"type":22},{"name":197,"class":117},{"id":221,"slug":222,"hasResults":11,"nctId":223,"briefTitle":224,"officialTitle":224,"acronym":225,"eligibilityCriteria":226,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":227,"targetDuration":4,"studyType":229,"phases":4,"briefSummary":230,"conditions":231,"keywords":233,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":236,"lastUpdatePostDateStruct":237,"startDateStruct":239,"completionDateStruct":241,"leadSponsor":243,"locationsCount":71},"100313324","three-dimensional-analysis-of-emmprin-on-conjunctival-epithelial-cells-surface-in-severe-dry-eye-syndrome-altesse-100313324","NCT03358979","Three-dimensional Analysis of EMMPRIN on Conjunctival Epithelial Cells Surface in Severe Dry Eye Syndrome (ALTESSE)","ALTESSE","Patients:\n\nInclusion criteria\n\n* 18 years and over\n* Severe eye dryness (grade 3 or 4) as defined by the International Dry Eye Work Shop (2007): Frequent symptoms, Impregnation of fluorescein at the conjunctival level, marked fluorescein staining at the corneal level, Tear Break Up Time ≤ 5 seconds (fluorescein test) Schirmer's test score without anesthesia ≤ 5mm at 5 minutes\n* Patients without eye treatment or patients undergoing long-term stable eye treatment for whom a new treatment is being introduced\n\nExclusion criteria - Known pregnancy or breastfeeding\n\nControl subjects:\n\nInclusion criteria\n\n\\- 18 years and over\n\nExclusion criteria\n\n* Wearer of contact lenses\n* Topical ocular treatment\n* Known pregnancy or breastfeeding",{"count":228,"type":22},100,"OBSERVATIONAL","Modifications of cell surface markers (including EMMPRIN) were observed in conjunctival epithelial cells during dry eye syndrome ; this study aims to describe the modifications of the repartition of these cell surface markers before and after initiation of a treatment.",[232,31],"Conjunctival Diseases",[232,31,234,235],"Antigens","CD147","2025-12-02",{"date":238,"type":36},"2025-12-08",{"date":240,"type":36},"2017-12-14",{"date":242,"type":22},"2027-03",{"name":244,"class":245},"Fondation Ophtalmologique Adolphe de Rothschild","NETWORK",{"id":247,"slug":248,"hasResults":11,"nctId":249,"briefTitle":250,"officialTitle":251,"acronym":4,"eligibilityCriteria":252,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":253,"enrollmentInfo":254,"targetDuration":4,"studyType":23,"phases":255,"briefSummary":257,"conditions":258,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":260,"lastUpdatePostDateStruct":261,"startDateStruct":263,"completionDateStruct":265,"leadSponsor":267,"locationsCount":4},"100613506","phase-4-switching-from-xiidra-to-tryptyr-100613506","NCT07267481","Switching From Xiidra to TRYPTYR","Efficacy of Switching Participants Treated With Xiidra to TRYPTYR","Inclusion Criteria:\n\n* Adults ≥18 years of age.\n* Have a history of DED for at least the past 6 months.\n* Are currently using Xiidra as directed by their eye care provider for ≥1 month.\n* Are symptomatic as determined with SPEED (≥7) and have an abnormal Schirmer test score \\[≥2 to \\\u003C10 mm\u002F5 min\\]) at Screening\u002FBaseline. If Shirmer only qualifies for one eye, that will be the study eye. If Shirmer qualifies for both eyes, the right eye will be the study eye.\n* Have corrected distance visual acuity of 20\u002F40 or better.\n* Willing to discontinue contact lens wear 24 hours prior to screening visit and throughout the study.\n\nExclusion Criteria:\n\n* Have a systemic health condition that is known to alter tear film physiology (e.g., primary and secondary Sjögren's syndrome).\n* Have a history of ocular surgery within the past 12 months.\n* Have a history of severe ocular trauma, active ocular infection or inflammation that is not dry eye related.\n* Punctal plugs in place for \\\u003C 3 months and\u002For Lacrifill in place for \\> 5 months.\n* Have ever used Accutane\n* Currently using ocular medications, including topical anti-inflammatory drops, (other than Xiidra) 1 month prior to enrollment\n* Any artificial tear use at enrollment must remain consistent throughout the study.\n* Are pregnant or breast feeding.\n* Have had a physical meibomian gland treatment withing 1 month of enrollment.\n* Initiated, discontinued or changed dose of a systemic medication known to cause ocular drying (e.g., antihistamines or tricyclic antidepressants) within 14 days of the screening visit.\n* Have a condition or be in a situation, which in the investigator's opinion, may put the participant at significant risk, may confound the results, or may significantly interfere with their study participation.","99 Years",{"count":228,"type":22},[256],"PHASE4","To determine the efficacy of switching participants who are being treated with Xiidra to acoltremon 0.003%.\n\nHypothesis: Switching to acoltremon 0.003% will greatly improve the signs and symptoms of participants who were being treated with Xiidra at 28 days post-treatment compared to baseline.",[29,30,31,259],"Eye Diseases","2025-11-25",{"date":262,"type":36},"2025-12-05",{"date":264,"type":22},"2025-12-15",{"date":266,"type":22},"2026-05-01",{"name":268,"class":117},"Southern College of Optometry",{"id":270,"slug":271,"hasResults":11,"nctId":272,"briefTitle":273,"officialTitle":273,"acronym":4,"eligibilityCriteria":274,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":253,"enrollmentInfo":275,"targetDuration":4,"studyType":23,"phases":277,"briefSummary":278,"conditions":279,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":285,"lastUpdatePostDateStruct":286,"startDateStruct":288,"completionDateStruct":290,"leadSponsor":292,"locationsCount":71},"100296157","clinical-applications-of-advanced-ophthalmic-imaging-100296157","NCT03135327","Clinical Applications of Advanced Ophthalmic Imaging","Observational Phase 1 Group\n\nInclusion Criteria:\n\n1. Self-reported normal healthy subjects;\n2. Clinical diagnosis of Alzheimer's Disease, mild cognitive impairment, multiple sclerosis, dry eye, myopia, diabetics and stroke;\n3. Who can keep the eye open for imaging.\n\nExclusion Criteria:\n\n1. who can not read and sign the ICF;\n2. who can not receiving ophthalmic imaging;\n3. who cannot tolerate bright light during imaging.\n\nInterventional Phase 2 Group:\n\nInclusion criteria\n\nThe participant will be eligible for entry in the study if s\u002Fhe:\n\n1. Is at least 18 years old and has full legal capacity to volunteer;\n2. Has read and signed the IRB Informed Consent Document;\n3. Is willing and able to follow participant instructions;\n4. Has clear corneas and crystalline lens;\n5. Initial visual acuities were 20\u002F80 or better;\n6. MTHFR C677TT homozygous, or MTHFR C677T\u002FA1298C compound heterozygous with mild to moderate micro-aneurismal vascular retinopathy disease;\n7. Hemoglobin A1c is 10 or less;\n8. Normotensive with or without medications;\n9. Without retinal capillary dropout or macular edema;\n10. Blood homocysteine \\> 9.\n\nExclusion criteria\n\nThe subjects will be ineligible for entry into the study if s\u002Fhe:\n\n1. Has an active ocular disease;\n2. Has had surgery or an eye injury within 6 months.",{"count":276,"type":22},5000,[54],"The purpose of this study is to determine the clinical application of advanced ophthalmic imaging devices such as optical coherence tomography (OCT), retinal function imager (RFI), slit-lamp biomicroscopy (SLB), PERG in diseased eyes and normal controls.\n\nThere are two phases in this study. The first phase is an observational phase which studies the eye in various conditions. The second phase is an interventional phase which studies the changes in the eyes after taking an over-the-counter medical food (Ocufolin) for 6 months.",[280,31,281,282,283,284],"Multiple Sclerosis","Diabetic Retinopathy","Presbyopia","Myopia","Dementia","2025-08-11",{"date":287,"type":36},"2025-08-12",{"date":289,"type":36},"2007-01-01",{"date":291,"type":22},"2029-12-31",{"name":293,"class":117},"University of Miami",{"id":295,"slug":296,"hasResults":11,"nctId":297,"briefTitle":298,"officialTitle":299,"acronym":4,"eligibilityCriteria":300,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":301,"targetDuration":4,"studyType":229,"phases":4,"briefSummary":303,"conditions":304,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":305,"lastUpdatePostDateStruct":306,"startDateStruct":308,"completionDateStruct":310,"leadSponsor":312,"locationsCount":71},"100254012","assessment-of-tft-by-oct-in-healthy-subjects-and-subjects-with-des-100254012","NCT02585414","Assessment of TFT by OCT in Healthy Subjects and Subjects With DES","Assessment of Tear Film Thickness by Optical Coherence Tomography in Healthy Subjects and Subjects With Dry Eye Disease","Inclusion Criteria:\n\nInclusion criteria for healthy volunteers\n\n* Men and women aged over 18 years\n* Normal findings in the medical history unless the investigator considers an abnormality to be clinically irrelevant\n* Normal ophthalmic findings, ametropia \\\u003C 6 Dpt.\n\nInclusion criteria for patients with DES:\n\n* Men and women aged over 18 years\n* DES patients will be included based on three questions:\n\n  * (1) \"Have you ever been diagnosed (by a clinician) as having dry eye syndrome?\"\n  * (2) \"Do you currently use artificial tear eyedrops or gel?\"\n  * (3) \"For the past three months or longer, have you had dry eyes? (This is described as a foreign body sensation with itching and burning, sandy feeling, not related to allergy).\"\n* Normal ophthalmic findings except dry eye syndrome\n\nExclusion Criteria:\n\n* Participation in a clinical trial in the 3 weeks preceding the study\n* Symptoms of a clinically relevant illness in the 3 weeks before the first study day\n* Wearing of contact lenses\n* Intake of dietary supplements in the 3 months preceding the study\n* History of glaucoma\n* Treatment with corticosteroids in the 4 weeks preceding the study to topical treatment with any ophthalmic drug in the 4 weeks preceding the study (topical lubricants for patients with DES are allowed)\n* Ocular infection or clinically significant inflammation\n* Ocular surgery in the 3 months preceding the study\n* Sjögren's syndrome\n* Stevens-Johnson syndrome\n* Pregnancy, planned pregnancy or lactating",{"count":302,"type":22},340,"Dry eye syndrome (DES) is a highly prevalent ocular condition with potential severe consequences for affected patients. DES can be either caused by decreased tear production or increased tear evaporation, both leading to an instable tear film. Despite many efforts, generally accepted methodologies to diagnose, assess the severity and monitor DES are still lacking. Moreover, widely used clinical methods such as tear break up time (BUT), fluorescein staining of the cornea or Schirmer test only poorly reflect patients´ complains.\n\nOne of the main problems in the diagnosis and treatment of DES is that the most critical component - the tear film itself - is difficult to characterize. The development of new ultra-high resolution optical coherence tomography systems allows now for the direct visualization of the human tear film and for the non-invasive in-vivo measurement of tear film thickness (TFT). The investigators could recently show that this system provides excellent reproducibility and is able to assess even subtle changes in TFT induced by therapeutic interventions. However, to which extent tear film thickness is associated with other standard clinical measures of DES is currently unknown. In the present study, the investigators set out to test the hypothesis that ocular TFT is a new and good surrogate parameter for the assessment of the severity of DES.\n\nConsequently, the aim of the study presented in this protocol is to investigate whether and if so, to what extent clinical signs of DES and reported symptoms are reflected in ocular TFT. For this purpose, a cross sectional study in healthy subjects and patients with DES will be performed. This should allow the investigators to more specifically characterize the role of the tear film in DES and to assess whether measurement of TFT with OCT can be a promising surrogate parameter for the diagnosis and the follow up of DES.",[31],"2025-05-20",{"date":307,"type":36},"2025-05-23",{"date":309,"type":36},"2017-08-31",{"date":311,"type":22},"2026-12",{"name":313,"class":117},"Medical University of Vienna",{"id":315,"slug":316,"hasResults":11,"nctId":317,"briefTitle":318,"officialTitle":319,"acronym":320,"eligibilityCriteria":321,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":322,"enrollmentInfo":323,"targetDuration":4,"studyType":23,"phases":325,"briefSummary":327,"conditions":328,"keywords":329,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":332,"lastUpdatePostDateStruct":333,"startDateStruct":335,"completionDateStruct":337,"leadSponsor":339,"locationsCount":71},"100557865","phase-1-limbal-stem-cell-derived-exosome-lsc-exo-eye-drop-for-treatment-of-dry-eye-100557865","NCT06543667","Limbal Stem Cell Derived Exosome (LSC-Exo) Eye Drop for Treatment of Dry Eye","A Clinical Study for Safety and Efficacy Evaluation of Limbal Stem Cell Derived Exosome (LSC-Exo) Eye Drop for Treatment of Dry Eye Syndrome","EXOIUMS","Inclusion Criteria:\n\n* Patients with complaints of burning or itching or feeling of a foreign body in the eye\n* Moderate and severe dry eye severity\n* Age between 18-70 years\n\nExclusion Criteria:\n\n* Previous history of eye surgery\n* Any disease that suppresses the immune system\n* Pregnancy and breastfeeding\n* Eyelid abnormalities\n* Use of eye drops in the past year except artificial tears and lubricating ointments\n* Use of systemic drugs that affect the tear film in last three months\n* Use of contact lenses in the last three months","70 Years",{"count":324,"type":22},30,[326],"PHASE1","The purpose of this study is to determine the safety and efficacy of Limbal Stem Cells derived Exosomes (LSC-Exo) in alleviation of dry eye symptoms",[31],[28,330,331],"Sjogren's Syndrome","Chronic Dry Eye","2025-04-30",{"date":334,"type":36},"2025-05-01",{"date":336,"type":36},"2024-08-01",{"date":338,"type":22},"2026-07-01",{"name":340,"class":117},"Iran University of Medical Sciences",{"id":342,"slug":343,"hasResults":11,"nctId":344,"briefTitle":345,"officialTitle":346,"acronym":347,"eligibilityCriteria":348,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":349,"targetDuration":4,"studyType":23,"phases":350,"briefSummary":351,"conditions":352,"keywords":354,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":358,"lastUpdatePostDateStruct":359,"startDateStruct":361,"completionDateStruct":363,"leadSponsor":364,"locationsCount":71},"100579973","efficacy-of-platelet-rich-plasma-injection-in-dry-eye-syndrome-100579973","NCT06831253","Efficacy of Platelet-Rich Plasma Injection in Dry Eye Syndrome","Efficacy of Restoration of Lacrimal Secretion After Injection of Platelet-Rich Plasma (PRP) Into the Lacrimal Gland in Severe Dry Eye Syndromes (ReLIPSSO)","ReLIPSSO","Inclusion Criteria:\n\n* Platelet counts, and clotting factors in the standarts\n* Presenting with severe dry keratoconjunctivitis diagnosed by an ophthalmologist\n\nExclusion Criteria:\n\n* Patients with significant fibrosis of the conjunctival portion of the lacrimal gland\n* Patients with complete stenosis of both lacrimal meatus in the treated eye",{"count":82,"type":22},[54],"The investigatror wants to show the efficacy of Platelet-Rich Plasma injection in lacrimal gland to restore the lacrimal secretion in patients presenting aqueous deficiency reponsible for severe dry eye syndrome.",[353,31],"Severe Dry Eye Syndromes",[31,355,356,357],"lacrimal gland","platelet-rich plasma","aqueuous deficiency","2025-03-18",{"date":360,"type":36},"2025-03-19",{"date":362,"type":36},"2025-03-17",{"date":338,"type":22},{"name":365,"class":117},"Centre Hospitalier Universitaire de Nice",{"id":367,"slug":368,"hasResults":11,"nctId":369,"briefTitle":370,"officialTitle":371,"acronym":4,"eligibilityCriteria":372,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":373,"targetDuration":4,"studyType":23,"phases":375,"briefSummary":376,"conditions":377,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":358,"lastUpdatePostDateStruct":378,"startDateStruct":379,"completionDateStruct":381,"leadSponsor":382,"locationsCount":4},"100545268","phase-1-study-to-evaluate-the-safety-and-tolerability-of-pro-190-ophthalmic-solution-compared-to-systane-ultra-on-the-ocular-surface-100545268","NCT06379685","Study to Evaluate the Safety and Tolerability of PRO-190 Ophthalmic Solution Compared to Systane Ultra® on the Ocular Surface.","Phase I Clinical Study to Evaluate the Safety and Tolerability of PRO-190 Ophthalmic Solution Compared to Systane Ultra® on the Ocular Surface of Ophthalmologically and Clinically Healthy Volunteers.","Inclusion Criteria:\n\n* Having the ability to voluntarily give their signed informed consent.\n* Clinically healthy subjects.\n* Being able to and willing to comply with scheduled visits, treatment plan, and other study procedures.\n* Age ≥ 18 years.\n* No history of contact lens wear\n* Women of childbearing potential who have not undergone Bilateral Tubal Occlusion (BTO \\[Tubal Ligation\\]), hysterectomy, or bilateral oophorectomy must ensure continuation (initiated ≥ 30 days prior to signing the ied consent form \\[ICF\\]) of the use of a hormonal contraceptive method or intrauterine device (IUD) during the study period.\n* Having vital signs within normal parameters.\n* Best corrected visual acuity (BCVA) of 20\u002F30 or better in both eyes.\n* Having an intraocular pressure ≥ 10 and ≤ 21 mmHg.\n\nExclusion Criteria:\n\n* History of hypersensitivity to any of the components of the drugs under investigation.\n* Use of ophthalmic medications from any pharmacological group.\n* Use of medications by any other route of administration.\n* In the case of women: being pregnant, breastfeeding, or planning to become pregnant within the study period.\n* Having participated in any clinical research study 30 days prior to inclusion in this study.\n* Having previously participated in this same study.\n* History of any chronic-degenerative disease, including Diabetes Mellitus or Systemic Arterial Hypertension.\n* Diagnosis of glaucoma or ocular hypertension.\n* Known diagnosis of liver or heart disease.\n* Presenting active inflammatory or infectious disease at the time of entry into the study.\n* Presenting unresolved lesions or traumas at the time of entry into the study.\n* Having been subjected to non-ophthalmological surgical procedures in the last 3 months.\n* Being or having an immediate family member (e.g., spouse, parent\u002Flegal guardian, sibling, or child) who is an employee of the research site or the sponsor, and who directly participates in this study.\n\nElimination Criteria\n\n* Withdrawal of their consent to participate in the study (informed consent form).\n* Occurrence of a serious adverse event, whether related or not to the interventions, that in the opinion of the principal investigator (PI) and\u002For the sponsor, could affect the patient's fitness to safely continue with the study procedures.\n* Non-tolerability or hypersensitivity to any of the compounds used during the tests -(fluorescein, tetracaine).\n* Non-tolerability or hypersensitivity to any of the drugs under investigation.\n* Adherence \\\u003C 80% determined by the subject's diary and corroborated by the final weight of the research products (RP) compared to the initial weight.",{"count":374,"type":22},32,[326],"This is a phase I clinical study to evaluate the safety and tolerability of PRO-190 ophthalmic solution through the incidence of unexpected adverse events, changes in Best Corrected Visual Acuity (BCVA), changes in ocular surface integrity, changes in the ocular comfort index (OCI) score, and IOP measurement compared to Systane Ultra®.",[29,30,31],{"date":360,"type":36},{"date":380,"type":22},"2025-12-30",{"date":195,"type":22},{"name":383,"class":43},"Laboratorios Sophia S.A de C.V.",{"id":385,"slug":386,"hasResults":11,"nctId":387,"briefTitle":388,"officialTitle":389,"acronym":4,"eligibilityCriteria":390,"healthyVolunteers":17,"sex":391,"minAge":392,"maxAge":393,"enrollmentInfo":394,"targetDuration":4,"studyType":23,"phases":396,"briefSummary":397,"conditions":398,"keywords":399,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":403,"lastUpdatePostDateStruct":404,"startDateStruct":406,"completionDateStruct":408,"leadSponsor":410,"locationsCount":71},"100581324","difference-of-tear-ferning-between-women-with-and-without-menopausal-100581324","NCT06848829","Difference of Tear Ferning Between Women with and Without Menopausal.","Difference of Tear Ferning Between Pre-and Post-menopausal Women and Between Post-menopausal Women with or Without Hormone Replacement Therapy (HRT)","Inclusion Criteria:\n\n* Aged between 20 and 65 years\n\nExclusion Criteria:\n\n* No evident ocular diseases such as cornea, cataracts, vitreous degeneration, glaucoma, and retinopathy.\n* Belong to vulnerable groups(pregnancy woman, prisoner, ethical minorities, economic or educationally disadvantaged subjects, disabled individuals such as those at terminal stage of tumorigenesis, blindness, terminal ill individuals)","FEMALE","20 Years","65 Years",{"count":395,"type":22},90,[54],"Application of tear ferning test for clinical dry eye diagnosis and menopause",[31],[400,401,402],"Dry Eye diagnosis","Tear ferning","menopause","2025-02-21",{"date":405,"type":36},"2025-02-27",{"date":407,"type":36},"2024-10-01",{"date":409,"type":22},"2025-10-01",{"name":411,"class":117},"Chung Shan Medical University",{"id":413,"slug":414,"hasResults":11,"nctId":415,"briefTitle":416,"officialTitle":416,"acronym":4,"eligibilityCriteria":417,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":418,"enrollmentInfo":419,"targetDuration":4,"studyType":23,"phases":421,"briefSummary":422,"conditions":423,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":424,"lastUpdatePostDateStruct":425,"startDateStruct":427,"completionDateStruct":429,"leadSponsor":431,"locationsCount":71},"100448595","study-of-platelet-rich-plasma-drops-to-moderate-clinically-significant-dry-eye-100448595","NCT05121493","Study of Platelet Rich Plasma Drops to Moderate Clinically Significant Dry Eye","Inclusion Criteria:\n\n* Subjects must be diagnosed with clinically significant dry eye.\n* Subjects have no active ocular disease or allergic conjunctivitis.\n* Subjects must not be using any topical ocular medications within two weeks prior to enrollment.\n* Subjects must be willing and able to follow instructions.\n* Subjects must have voluntarily agreed to participate in the study by signing the statement of informed consent.\n* Subjects must meet plasma donor criteria as established by University of Rochester Transfusion Medicine \\& Blood Bank.\n\nExclusion Criteria:\n\n* Is pregnant at the time of enrolment in the study determined by urine pregnancy test.\n* Is currently on a course of antibiotics\n* Is considered by the Investigator to not be a suitable candidate for participation and are not at risk for glaucoma.\n* Is considered by the University of Rochester Transfusion Medicine \\& Blood Bank not a suitable candidate for blood donation.","75 Years",{"count":420,"type":22},15,[54],"This is a single center double-masked study with up to four visits. Subjects who have been diagnosed with dry-eye syndrome at Flaum Eye Institute will be enrolled. The purpose of the study is to determine if using platelet rich plasma drops can improve clinically significant dry eye in patients and determine if there is a difference with using two different uses of the plasma tear drops: platelet rich plasma tears and plasma tears without platelets.",[31],"2024-11-22",{"date":426,"type":36},"2024-11-26",{"date":428,"type":22},"2025-10-15",{"date":430,"type":22},"2026-12-15",{"name":432,"class":117},"University of Rochester",{"id":434,"slug":435,"hasResults":11,"nctId":436,"briefTitle":437,"officialTitle":438,"acronym":4,"eligibilityCriteria":439,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":440,"targetDuration":4,"studyType":23,"phases":441,"briefSummary":442,"conditions":443,"keywords":444,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":447,"lastUpdatePostDateStruct":448,"startDateStruct":450,"completionDateStruct":452,"leadSponsor":454,"locationsCount":71},"100556504","phase-4-itear-single-center-open-label-single-arm-study-100556504","NCT06525961","iTear Single-center, Open-label, Single-arm Study","A Single-center, Open-label, Single-arm Study to Evaluate the Effectiveness and Safety of Extra Nasal Neurostimulator in Patients With Dry Eye Disease Dissatisfied With Artificial Tears","Inclusion Criteria:\n\nEach patient must meet all the following criteria to be enrolled in this study:\n\n1. Provided informed consent, approved by the Institutional Review Board (IRB), to participate in the study.\n2. Reported use of artificial tears for DED within 30 days of Visit 1.\n3. Ocular Surface Disease Index (OSDI) ≥ 23 (with no more than 3 N\u002FA in the answers).\n4. Anesthetized Schirmer Test Score ≤ 10 mm\u002F5 min in at least one eye.\n\nExclusion Criteria:\n\nPatients who meet any of the following criteria will be excluded from the study:\n\n1. Used extranasal or intranasal neurostimulator within 30 days of Visit 1.\n2. Participation in any clinical trial with an investigational drug or device within 30 days of Visit 1.\n3. In the opinion of the investigator, any condition that could impair study participation\u002Focular evaluation or the potential risks of participation outweigh the potential benefits.",{"count":324,"type":22},[256],"This study aims to evaluate the effectiveness and safety of a device, iTEAR100 Neurostimulator (the device), which is designed to help people with Dry Eye Disease (DED) who are not satisfied with using artificial tears. The study will last three months and take place at one location. Thirty participants will use the iTEAR100 Neurostimulator, which stimulates the outside of the nose to help with dry eye symptoms.\n\nParticipants will have three main visits: one at the start (Day 0), one after 30 days (Day 30), and one at the end of the study (Day 90). For the first 30 days, they will use the device twice a day for 30 seconds on each side of the nose. After that, they will use it as needed for the next 60 days.\n\nBefore starting the treatment, participants will undergo tests to measure their initial eye condition. The effectiveness of the device will be checked by comparing these baseline measurements to those taken on Day 30 and Day 90. Participants will also fill out a questionnaire about their eye symptoms on Day 14.\n\nThe main measure of success is how much the participants' symptoms improve on the Ocular Surface Disease Index (OSDI) from Day 0 to Day 30. Other measures include changes in tear production, tear quality, and eye health from Day 0 to Days 30 and 90. Participants' safety will be monitored by tracking any adverse events (side effects) throughout the study.",[28,31,29,107],[29,445,31,446],"DED","Meibomian Gland Dysfunction (MGD)","2024-07-23",{"date":449,"type":36},"2024-07-29",{"date":451,"type":22},"2024-08",{"date":453,"type":22},"2026-01",{"name":116,"class":117}]